Addario Lung Cancer Medical Institute

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Addario Lung Cancer Medical Institute sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 1 currently recruiting 2 completed upper quartile by trial count

Addario Lung Cancer Medical Institute: 8 sponsored US clinical trials, 1 recruiting.

Addario Lung Cancer Medical Institute sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. The most-studied condition in this pipeline is Kras P.G12C, with 1 trials.

Upper-quartile sponsor footprint

Addario Lung Cancer Medical Institute sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING

Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies

NCT06486428
ACTIVE NOT RECRUITING

Studying Pathways of Resistance in KRAS-driven Cancers

NCT05272423
ACTIVE NOT RECRUITING

Epidemiology of Young Lung Cancer - Survey

NCT04640259
NOT YET RECRUITING

A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)

NCT07075627
TERMINATED

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

NCT04676386
COMPLETED

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

NCT03833934
TERMINATED

Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

NCT03553550
COMPLETED

ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors

NCT03497624

Therapeutic Areas

Kras P.G12C 1
NSCLC 1
Small-cell Lung Cancer 1

What is open in the Addario Lung Cancer Medical Institute pipeline

1 recruiting of 8 indexed (13% open); 2 completed (25%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Kras P.G12C (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Addario Lung Cancer Medical Institute: open-pipeline peers nationwide

Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Addario Lung Cancer Medical Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%10%20%30%40% Total trials Recruiting share Addario Lung Cancer Medical InstituteAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)American UniversityAnnexonAnsun BiopharmaAvidity Biosciences
Addario Lung Cancer Medical Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Addario Lung Cancer Medical Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Addario Lung Cancer Medical Institute page

8 registered trials is a research-attention snapshot, not an endorsement of Addario Lung Cancer Medical Institute or any single study.

  • 1 of Addario Lung Cancer Medical Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Kras P.G12C is the condition Addario Lung Cancer Medical Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Kras P.G12C trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Addario Lung Cancer Medical Institute pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.